The development of CTL responses was consistently associated with the induction of viral escape mutations in the targeted epitopes, which was further linked to the development of novel CTL responses towards the new epitope variants.
Recent studies have also suggested their role in the regulation of bacterial growth and development through novel response regulators [ 52] by turnover of cyclic diguanosine monophosphate.
Current assays available to the practicing breast oncologist are largely based upon the presence or absence of these cells, but in the future it is hoped that biologic characteristics of CTCs, such as protein or mRNA expression, will be used in risk assessment, tailoring of treatment, monitoring of response, and development of novel therapeutic agents for patients with breast cancer.
Altogether, our study provides new insights into the cellular mechanisms and the interplay between them in regulating readthrough and may enable the development of novel drugs aimed to improve the response to readthrough therapies for many human genetic diseases caused by PTCs.
These results provide new insights into the cellular mechanisms and the interplay between them in regulating readthrough and may enable the development of novel drugs aimed to improve the response to readthrough therapies for many human genetic diseases caused by PTCs.
Understanding the mechanism and effects of PLA2 upregulation in AD brain may help in the development of novel strategies to inhibit the inflammatory responses and delay AD progression.
The development of novel influenza vaccines inducing a broad immune response is an important objective.
In the past decade, cancer immunotherapy studies have extensively focused on the attempt to exploit the highly specific nature of the adaptive immune response for the development of novel treatments.
It is therefore assumed that upregulation of E2F1 has been implicated in oncogenesis, prognosis, and prediction of therapeutic response together with development of novel target therapy.
Such data can then be extrapolated to understanding targeted therapy response and potential development of novel treatment agents, with a view to modifying or personalizing therapy.
